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Abstract
The recent origin and great evolutionary potential of HIV imply that the virulence of the virus might still be changing, which
could greatly affect the future of the pandemic. However, previous studies of time trends of HIV virulence have yielded
conflicting results. Here we used an established methodology to assess time trends in the severity (virulence) of untreated
HIV infections in a large Italian cohort. We characterized clinical virulence by the decline slope of the CD4 count (n=1423
patients) and the viral setpoint (n=785 patients) in untreated patients with sufficient data points. We used linear regression
models to detect correlations between the date of diagnosis (ranging 1984–2006) and the virulence markers, controlling for
gender, exposure category, age, and CD4 count at entry. The decline slope of the CD4 count and the viral setpoint displayed
highly significant correlation with the date of diagnosis pointing in the direction of increasing virulence. A detailed analysis
of riskgroups revealed that the epidemics of intravenous drug users started with an apparently less virulent virus, but
experienced the strongest trend towards steeper CD4 decline among the major exposure categories. While our study did
not allow us to exclude the effect of potential time trends in host factors, our findings are consistent with the hypothesis of
increasing HIV virulence. Importantly, the use of an established methodology allowed for a comparison with earlier results,
which confirmed that genuine differences exist in the time trends of HIV virulence between different epidemics. We thus
conclude that there is not a single global trend of HIV virulence, and results obtained in one epidemic cannot be
extrapolated to others. Comparison of discordant patterns between riskgroups and epidemics hints at a converging trend,
which might indicate that an optimal level of virulence might exist for the virus.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) is a recent
pathogen of humans, estimated to have jumped to the human
species about 80 years ago [1]. The virus may still be adapting to
humans, and this evolution may affect also its ability to cause
disease. There is evidence for heritable variation in viral traits that
influence the virulence of the virus (severity of the infection) [2–5],
which creates the conditions for the evolution of virulence.
Multiple studies have attempted to assess time trends of HIV
virulence, and have found increasing [6–11], stable [12–17], or
decreasing [18,19] virulence. The discrepancies may arise either
from genuine differences between the study populations or from
differences in the methodology used to quantify virulence.
Comparing results from different studies and assessing global
trends require the use of the same methodology in different
geographical areas and epidemics. Here we use a methodology
developed for an earlier analysis of the Swiss HIV Cohort Study
[17], on an Italian cohort of comparable size. Our findings
(increasing virulence in Italy vs. stable virulence in Switzerland)
with the same methodology indicate that genuine differences exist
between different epidemics. In addition, in the Italian cohort we
found different patterns of virulence among the major exposure
categories, indicating the possibility of relatively isolated sub-
epidemics within the same country. Finally, we note that any
measure of clinical virulence combines the effects of both host and
virus factors, and must therefore be interpreted with caution. Our
results are consistent with a time trend towards more virulent
viruses (either by local evolution or by the introduction and spread
of more virulent viruses from other epidemics); however, we could
not exclude the effect of host factors.
Results
Time trend towards steeper CD4 slopes
The most direct measure of virulence available in untreated
HIV infections is the rate of decline of the CD4 cell count in the
blood. After a data selection procedure (see Methods), the CD4
slope could be calculated for 1423 patients. The earliest date of
confirmed infection ranged between 1984–2005; the median
number of CD4 counts used in the calculation of the slope was 9,
the median baseline CD4 count was 596 cells/mL, and median age
PLoS Pathogens | www.plospathogens.org 1 May 2009 | Volume 5 | Issue 5 | e1000454was 28.9 years at entry. The median CD4 slope was 250.4 cells/
mL/year. The representation of the major exposure categories was
as follows: intravenous drug-users (IDUs) 46.3%, heterosexuals
(HETs) 36.6%, and men having sex with men (MSM) 17.1%;
31.9% of the patients were females. The CD4 slope displayed
highly significant correlation with the date of confirmed infection
(Spearman’s rank correlation test: rho=20.16, p,0.001; unad-
justed effect: 21.7 cells/mL/year/year, 95% CI: 22.3–21.1), in
the direction of steeper CD4 slopes over the time span of the
cohort. To account for potential confounding effects, we
performed multivariate linear regression controlling for gender
and exposure category (reference levels were male and IDU), age
at the date of confirmed infection and baseline CD4+ cell count;
the primary variable of interest was the date of confirmed
infection. The distribution of the CD4 slopes had very long tails,
with 10% of the data responsible for about 70% of the range. To
approach normality, we therefore discarded outliers below the 5%
and above the 95% quantiles. 1279 patients were included in the
main analysis; the characteristics of this group are summarized in
Table 1 according to exposure category. Best model fit was
achieved after merging the HET and MSM exposure categories.
The effect of the date of confirmed infection was highly significant
(22.0 cells/mL/year/year; 95% CI: 22.7–21.3; p,0.001) in the
regression analysis, confirming the time trend toward steeper CD4
slopes. The effect of date on the virulence markers in the main
analyses is summarized in Table 2. The baseline CD4 count also
had highly significant effect (20.048 per year; 95% CI: 20.058–
20.039; p,0.001), indicating that the rate of loss slows down at
lower CD4 counts, as has been observed before [7,12,17].
Furthermore, the HET and MSM exposure categories were
associated with significantly faster CD4 decline compared with
IDUs (227.6 cells/mL/year; 95% CI: 250.4–24.9; p=0.017),
and the interaction between the merged MSM/HET exposure
category and the date of confirmed infection displayed borderline
significance (0.90 cells/mL/year/year; 95% CI: 20.0–1.8;
p=0.056), indicating that the time trend may be less pronounced
in these riskgroups. All other factors and interaction terms were
dropped from the regression design due to lack of significance
during model simplification (see Methods). To further investigate
potential differences between the riskgroups, we carried out
separate regression analyses restricted to each category. The effect
of date was strongest in the analysis of IDUs (unadjusted effect:
21.7 cells/mL/year/year, 95% CI: 22.4–21.1; adjusted effect:
22.0 cells/mL/year/year; 95% CI: 22.6–21.4; p,0.001), weaker
among HETs (unadjusted effect: 21.1 cells/mL/year/year, 95%
CI: 22.0–20.3; adjusted effect: 21.3 cells/mL/year/year; 95%
CI: 22.2–20.3; p=0.008) and weakest in MSM (unadjusted
effect: 20.6 cells/mL/year/year, 95% CI: 21.7–0.6; adjusted
effect: 21.01 cells/mL/year/year; 95% CI: 22.16–0.14;
p=0.086), where it failed to reach significance. Factors for
adjustment retained after model simplification were baseline CD4
count in all three riskgroups, and also gender and age in the HET
exposure category (not shown).
The analysis of the point estimates of the CD4 slope per patient
cannot account for the misspecification of the slope of any one
individual. To ensure reliable estimation, we required five CD4
measurements for the estimation of the slope; however, this
requirement introduced a selection bias against fast progressors,
who cannot accumulate sufficient data points before starting
therapy. We therefore assessed time trends in the CD4 slope also
with a mixed-effect model fitted to the original CD4 count data.
The model included the same fixed effects as the general linear
model, plus random intercept and slope to account for the
correlation of repeated measurements within each individual. We
included patients with at least three CD4 counts; this more relaxed
selection criterion increased sample size to 1889 patients (the
characteristics of this group are shown in Table 1). The results of
the analysis were consistent with the findings from the linear
regression model (Table 2).
Time trend towards increasing viral setpoint
The magnitude of virus load in the blood after the resolution of
primary infection (‘‘viral setpoint’’) has been shown to correlate
with the rate of disease progression [20] and was therefore chosen
as our second measure of virulence. Following data selection (see
Methods), we calculated the setpoint for 785 patients as the mean
log virus load in each patient. The date of confirmed infection
ranged between 1996–2006; the median number of RNA
measurements used for the calculation of the setpoint was 7, the
median baseline CD4 count was 560 cells/mL, and the median age
at entry was 34.1 years. The median setpoint was 4.21 log10 RNA
copies/mL. The representation of the major exposure categories
was as follows: heterosexuals 51%, MSM 29% and IDUs 20%;
30.6% of the patients were females. The characteristics of the
study group are summarized in Table 1 according to exposure
category. The setpoint displayed highly significant correlation with
the date of confirmed infection (Spearman’s rank correlation test:
rho=0.19, p,0.001; unadjusted effect: 0.062 log10 RNA copies/
mL/year, 95% CI: 0.038–0.085), indicating an increasing trend
over time. To account for potential confounding effects, we
performed multivariate linear regression controlling for gender
and exposure category (reference levels were male and HET), age
at the date of confirmed infection and baseline CD4+ cell count;
the primary variable of interest was the date of confirmed
infection. The effect of the date of confirmed infection was highly
significant (0.043 log10 RNA copies/mL/year, 95% CI: 0.019–
0.066; p,0.001) in the regression analysis, confirming the time
trend toward increasing setpoints. Higher baseline CD4 count was
associated with lower virus load (29.38610
24 log10 RNA copies/
mL/cell/mL, 95% CI: 21.25610
23–26.30610
24;p ,0.001)
except among IDUs (IDU 6 baseline CD4 count: 0.001 log10
RNA copies/mL/cell/mL, 95% CI: 5.55610
24–1.45610
23;
p,0.001). Female gender was associated with lower virus load
(20.24 log10 RNA copies/mL, 95% CI: 20.38–20.11; p,0.001)
and higher age correlated with lower virus load in the IDU
Author Summary
The AIDS epidemic claims more lives per year than any
other infectious disease, even though its cause, the Human
Immunodeficiency Virus (HIV), is the youngest of all major
human pathogens. The recent origin and great evolution-
ary potential of the virus raise the possibility that the virus
might still be adapting to humans. Of primary interest is
whether the virulence of the virus, i.e. its ability to cause
disease, has been changing over time. Unfortunately,
previous results have yielded conflicting results. We
investigated time trends of virulence in the Italian HIV
epidemic and found increasing virulence. The use of an
established methodology allowed, for the first time, direct
comparison with results obtained in other epidemics. The
comparisons revealed that genuine differences exist in the
trends of HIV virulence between different epidemics. Thus,
there is no single time trend of HIV virulence worldwide.
Our results are consistent with the hypothesis of increasing
HIV virulence; however, clinical virulence combines viral
and host factors, and the effect of host factors could not
be excluded in our analysis.
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copies/mL/year, 95% CI: 20.036–20.016; p,0.001). All other
factors (including riskgroup) and interaction terms were dropped
from the regression design due to lack of significance during model
simplification. To further explore potential differences between
riskgroups we carried out separate regression analyses restricted to
each category. The effect of date proved strongest among MSM
(unadjusted effect: 0.057 log10 RNA copies/mL/year, 95% CI:
0.019–0.096; adjusted effect: 0.050 log10 RNA copies/mL/year,
95% CI: 0.012–0.088, p=0.001), weaker among HET (unadjust-
ed effect: 0.047 log10 RNA copies/mL/year, 95% CI: 0.017–
0.081; adjusted effect: 0.037 log10 RNA copies/mL/year, 95%
CI: 0.004–0.065, p=0.026) and weakest among IDU (unadjusted
effect: 0.042 log10 RNA copies/mL/year, 95% CI: 20.023–
0.108, p=0.2; no factor had significant effect for adjustment),
where it failed to reach significance. Factors for adjustment
retained after model simplification included the baseline CD4
count for HETs and MSM, and gender in the HET exposure
category (with female gender associated with lower setpoint as in
the main analysis). Because the distribution of setpoints displayed
considerable negative skew due to a long tail of low setpoints, we
repeated all setpoint analyses after discarding low setpoint values
to ensure normality. The results (including the effect of the date of
confirmed infection) were consistent with those of the analyses
performed on the complete dataset.
Increasing setpoints contributed little to the time trend
of CD4 slopes
We thus observed consistent trends of increasing virulence
towards both faster CD4 decline and increasing setpoints during
the time span of the cohort. Because higher setpoints have been
associated with faster disease progression [20] and faster CD4
decline [17], we next asked to what extent increasing setpoints
might have been responsible for the trend towards steeper CD4
slopes in our dataset. Estimates for both the CD4 slope and the
viral setpoint were available for 484 patients. Consistent with
earlier results, the CD4 slope was negatively correlated with the
setpoint (Spearman rank correlation test: rho=20.20, p,0.001;
unadjusted effect: 211.8 cells/mL/year/log10 RNA copies/mL,
95% CI: 217.0–26.6). To dissect the contribution of increasing
setpoints and other time-dependent factors to the trend towards
steeper CD4 decline, we performed an extended regression
Table 1. Demographic and clinical characteristics of the study groups included in the various analyses.
Exposure category
Heterosexual IDU MSM
CD4 slope analyses
Linear regression model
Number of patients 467 605 207
Female 289 (61.9%) 128 (21.1%) –
Median Interquartile range Median Interquartile range Median Interquartile range
Date of confirmed infection 27/10/98 24/11/92–18/10/01 10/01/90 01/07/87–05/11/93 10/01/00 26/01/94–03/07/02
Age at confirmed infection (y) 30.80 26.08–38.36 26.17 23.27–30.18 31.41 26.75–39.65
Baseline CD4+ cell count (cells/mL) 600 472–742 585 449–796 567 480–735.5
CD4 slope (cell/mL/year) 258.37 296.42–229.34 242.4 273.50–219.89 254.60 293.90–232.38
Mixed-effect model
Number of patients 690 845 354
Female 411 (59.6%) 174 (20.6%) –
Median Interquartile range Median Interquartile range Median Interquartile range
Date of confirmed infection 02/05/99 16/11/93–24/06/02 12/12/90 10/01/88–09/05/95 10/03/01 24/01/95–29/09/03
Age at confirmed infection (y) 31.86 26.53–39.68 26.60 23.57–31.05 33.02 27.19–40.81
Baseline CD4+ cell count (cells/mL) 563 428–717 562 414–775 560 459–728
Viral setpoint analysis
Number of patients 400 157 228
Female 202 (50.5%) 38 (24.2%) –
Median Interquartile range Median Interquartile range Median Interquartile range
Date of confirmed infection 15/10/01 10/01/00–17/09/03 28/11/00 27/10/98–13/01/03 26/10/02 07/02/01–07/05/04
Age at confirmed infection (y) 34.68 29.13–42.12 33.43 29.75–37.51 34.45 27.87–41.10
Baseline CD4+ cell count (cells/mL) 568.5 428–716.5 534 405–729 551.5 437–708
Setpoint (log10 RNA copies/mL) 4.17 3.73–4.55 4.00 3.26–4.40 4.35 3.93–4.66
The three virulence analyses could be performed on different, albeit overlapping, subsets of the cohort. In the early years, RNA measurements were not yet available,
while recently enrolled patients do not have sufficient data points for the calculation of the CD4 slope. Statistics of the linear regression model of the CD4 slope refer to
the subset stripped of outliers below the 5% and above the 95% percentiles; this subset was used in the regression analyses. The mixed-effect model accommodated
more patients due to less stringent inclusion criteria. The small number of IDUs in the viral setpoint analysis reflects their diminished proportion in the cohort by the
time RNA assays have become available.
IDU, intravenous drug users; MSM, men having sex with men.
doi:10.1371/journal.ppat.1000454.t001
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explanatory variable to the earlier regression design. However,
because this subset had a much later median date (due to the
requirement of viral setpoint), we first tested the original
multivariate regression design (without setpoint). The effect of
the date of confirmed infection remained highly significant in this
more recent subset (24.4 cells/mL/year/year; 95% CI: 26.2–
22.6; p,0.001), and proved even stronger than in the main
analysis. Further factors retained after model simplification
included gender, baseline CD4 count, age and the interaction
between gender and age. We then repeated the analysis including
also setpoint as explanatory variable (the effect of age and the
interaction between gender and age were dropped due to lack of
significance in this design). The effect of setpoint proved highly
significant (214.4 cells/mL/year/log10 RNA copies/mL, 95% CI:
219.6–29.3, p,0.001); however, the effect of the date of
confirmed infection also remained significant (23.4 cells/mL/
year/year; 95% CI: 25.2–21.7; p,0.001), and its strength
decreased by only 22.2% compared with the analysis not
controlling for setpoint. This result suggests that the bulk of the
time trend towards steeper CD4 slopes was independent of
variation (increase) in the setpoint. We tested also the inclusion of
higher order terms in the setpoint into the regression model, but
these proved not to be significant. Furthermore, calculating the
expected effect of the increasing setpoints on the CD4 slopes by
multiplying the unadjusted date coefficient of the setpoint (0.062
log10 RNA copies/mL/year, as obtained earlier) with the setpoint
coefficient of the CD4 slope (214.4 cells/mL/year/log10 RNA
copies/mL) yields a result (0.89 cells/mL/year/year) that is
consistent with the decrease in the effect of date (0.98 cells/mL/
year/year) upon the inclusion of the setpoint in the analysis of the
CD4 slopes. Using mixed-effect models, we could repeat the
analyses on a considerably larger patient set due to the less
stringent selection criteria (1120 individuals had three of more
CD4 counts and an estimate for the setpoint), and the effect of date
was consistent with the results of the linear regression analysis
(Table 2). We thus conclude that the observed increase in the
setpoints had a relatively small contribution to the time trend
towards steeper CD4 slopes.
Fine-scale patterns of virulence over time
Finally, to visualize short-term trends in the virulence markers,
we plotted a moving average of both markers (Figure 1). Each point
in the graphs represents the averaged value of 50 patients and is
dated to their mean date of confirmed infection. The figure reveals
that the trends towards increasing virulence (steeper CD4 slope and
higher setpoint) have been stable throughout the time span of the
cohort, with short-term fluctuations superimposed over the
underlying long-term trend. We also calculated moving averages
of both virulence markers in the major riskgroups separately
(Figure 2). This fine-scale representation suggests two stages in the
time evolution of CD4 slopes withinthe riskgroups: in the first stage,
IDUs lost their initial advantage of slower CD4 decline compared
with HETs and MSM. After the convergence of the three
categories, the second half of the observed epidemic has been
characterized by a steady coupled trend towards steeper CD4 slopes
in all groups. This observation also explains why the difference in
effect of date between riskgroups lost significance in the more recent
Table 2. Estimated effects of the date of confirmed infection on the markers of disease progression.
Statistical model (dependent variable) Number of patients Estimate (per year) 95% CI p
Rate of CD4 decline (cells/mL/year)
Unadjusted effect of date 1423 21.69 22.29–21.09 ,0.001
General linear model 1279
Effect of date 22.00 22.69–21.31 ,0.001
Date6(HET or MSM) 0.89 20.02–1.81 0.056
Mixed-effect model 1889
Effect of date 21.86 22.47–21.25 ,0.001
Date6MSM 1.10 20.01–2.22 0.05
Viral setpoint (log10 RNA copies/mL)
Unadjusted effect of date 785 0.062 0.038–0.085 ,0.001
General linear model 785
Effect of date 0.043 0.019–0.066 ,0.001
Rate of CD4 decline in patients with setpoint data
(cells/mL/year)
Unadjusted effect of date 484 23.71 25.52–21.90 ,0.001
General linear model 484
Effect of date (unadjusted for setpoint) 24.42 26.21–22.63 ,0.001
Effect of date (adjusted for setpoint) 23.44 25.19–21.68 ,0.001
Mixed-effect model 1120
Effect of date (unadjusted for setpoint) 23.85 24.33–23.37 ,0.001
Effect of date (adjusted for setpoint) 23.35 23.85–22.85 ,0.001
General linear models of the rate of CD4 decline were fitted to the estimated CD4 slopes per patient; mixed-effect models were fitted to the original CD4 count data.
Date refers to the earliest date of confirmed infection in each patient. Further co-factors included gender, riskgroup, baseline CD4 count, age and interaction terms;
stepwise elimination of non-significant factors was performed based on likelihood ratio tests. Effects not related to date are not shown.
CI, confidence interval; HET, heterosexual; MSM, men having sex with men.
doi:10.1371/journal.ppat.1000454.t002
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in the viral setpoint seem to be strongly coupled between HETs and
MSMwith arecentdecelerationofthe increasing trend;thesetpoint
of IDUs seems to have fluctuated with no clear trend. Fine-scale
resolution of time trends by moving averages thus allows a better
interpretation of the results of the regression analyses. In particular,
the slower CD4 decline of IDUs was restricted to the early years of
the epidemic, and the estimated faster trend towards steeper slopes
reflects the early convergence of this riskgroup to the others.
Discussion
We found robust time trends both in the rate of CD4 decline
and in the viral setpoint towards increasing virulence in untreated
patients of the MASTER cohort. Over two decades of
observations, the rate of CD4 decline in newly diagnosed
infections has almost doubled, while the viral setpoint has been
increasing at a rate of about one log per 16 years since RNA
measurements had become available. The finding of increasing
virulence is consistent with some [6–11], but not all [12–19] earlier
studies of time trends of HIV virulence in various countries.
Previously, it has been unclear whether discrepancies between
studies of virulence arose from differences of how virulence was
quantified, or they reflected genuine differences between geo-
graphical regions and cohorts. Importantly, we used a method-
ology adopted from an earlier analysis [17], which found stable
levels of HIV virulence in Switzerland, over approximately the
Figure 1. Moving averages of the CD4 slope and the viral setpoint. The figure reveals considerable short-term fluctuations over a steady
trend towards steeper CD4 slopes (A) and higher setpoints (B). Each point represents the averaged value of 50 patients and is dated to their mean
date of confirmed infection. The window of averaging moved along the list of patients sorted according to the date of confirmed infection: the first
point represents the average of the first 50 patients, the second point represents the average calculated over the second through the 51
st patient,
etc. The same datasets were used as in the multivariate regression analyses, i.e. outliers below the 5% and above the 95% quantiles were removed
from the set of CD4 slopes.
doi:10.1371/journal.ppat.1000454.g001
Figure 2. Moving averages of the CD4 slope and the viral setpoint per riskgroup. The figure shows time trends of the CD4 slope (A) and
the viral setpoint (B) in the heterosexual (HET, black dots), intravenous drug-user (IDU, red dots), and men having sex with men (MSM, blue dots)
exposure categories. This fine-scale representation suggests two stages in the time evolution of CD4 slopes within the riskgroups: in the first stage,
IDUs lost their initial advantage of slower CD4 decline compared with HETs and MSM. After the convergence of the three categories, the second half
of the observed epidemic has been characterized by a steady coupled trend towards steeper CD4 slopes in all groups. Trends in the viral setpoint
seem to be strongly coupled between HETs and MSM with a recent deceleration of the increasing trend; the setpoint of IDUs seems to have
fluctuated with no clear trend. Each point in the graphs represents the averaged value of 50 patients and is dated to their mean date of confirmed
infection. The window of averaging moved along the list of patients sorted according to the date of confirmed infection: the first point represents the
average of the first 50 patients, the second point represents the average calculated over the second through the 51
st patient, etc. The same datasets
were used as in the multivariate regression analyses, i.e. outliers below the 5% and above the 95% quantiles were removed from the set of CD4
slopes.
doi:10.1371/journal.ppat.1000454.g002
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the same methods ensures that the discrepancy reflects genuine
differences in the temporal pattern of virulence between the Italian
and the Swiss cohorts. This observation indicates that there is not
a single ‘‘global trend’’ of HIV virulence, and results obtained in
one local epidemic cannot be extrapolated to others. It also implies
that correlating different markers of virulence will require the
study of the same population with the different methods. Of
particular interest would be the correlation of clinical markers, as
used in this study, and replicative capacity [10,19] as ‘‘top’’ and
‘‘bottom’’ measures of virulence. Replicative capacity is easy to
measure for individual virus isolates; however, its relationship to
pathogenic effects has been shown to be quite complex [21,22].
We note that our ‘‘empirical’’ measures of virulence reflect the
combined effect of both viral and non-viral (host or environmental)
factors, and our findings are therefore not direct evidence for virus
evolution. In addition to the factors incorporated in our analyses
(gender, riskgroup, age), the progression of HIV infections has
been shown to be influenced by host genetic factors [23], co-
infections [24,25] and socioeconomic factors [26]. Observed time
trends could, in principle, reflect changes in any of these
categories, and our data did not allow us to test or exclude the
effect of such host factors. Our results are consistent with time
trends in the viruses circulating in the cohort (either by evolution
or by repeated introductions), but do not provide direct evidence
or test for this hypothesis. The ultimate goal for future studies
would be to identify viral factors contributing to virulence.
Transmitted drug resistance has been associated with faster
CD4 decline in the first year of infection [27], the spread of
resistance mutations might thus also have contributed to the
observed trend in the CD4 slopes. However, the same trend
existed in the pre-HAART era and most patients in our cohort
were probably diagnosed after the first year of infection, which
indicate the effect of other factors. We have also tested whether the
criteria for starting therapy have changed over the time span of the
cohort: the last CD4 count before the initiation of therapy showed
a temporary peak around the beginning of the HAART era, but
no trend over the studied period. A further potential confounding
factor arises from our data selection procedure, which required
three RNA measurements and five CD4 counts in untreated
individuals to qualify for the estimation of the setpoint and the
CD4 slope. These criteria selectively remove fast progressors, who
may not have sufficiently long untreated disease history to
accumulate the required number of measurements. However,
such biased sampling should actually dampen a trend towards
faster progressors and cannot have generated the observed trends
as an artefact. Using mixed-effect models for the estimation of the
CD4 slope, we were able to use less stringent selection conditions,
and obtained consistent results. Finally, the earliest date of
confirmed infection probably has a varying time lag compared
to the true date of infection in the patients, which introduces
variation in the disease stage at entry and uncertainty in the timing
of infections. To minimize the effect of variation in the disease
stage, we discarded the data points potentially associated with late-
stage disease, and we also explicitly accounted for disease stage by
controlling for the initial CD4 count. Uncertainties in the timing of
infections may have contributed to short-term fluctuations: in
particular, the temporary reversal of the CD4 slope trend around
1996 (Figure 1) might have resulted from an elevated proportion of
slow progressors among the newly diagnosed cases due to
increased willingness for testing after the introduction of HAART.
However, the effect of fluctuations in the time lag must average out
in the long run, and therefore cannot generate, nor hide long-term
trends.
We also found differences in the time trends of virulence
between riskgroups, which raises the possibility that the epidemics
of the main exposure categories might have been founded by
independent introductions of the virus. The strongest effect was
the finding of a faster trend towards steeper CD4 slopes among
IDUs, who initially had the slowest CD4 decline among the
riskgroups. This suggests a plausible scenario that the IDU
epidemic was by chance founded by a virus strain of reduced
virulence, and occasional contact between the riskgroups later
transmitted more virulent (and apparently fitter) viruses into this
group. This hypothesis could be tested in the future by
phylogenetic analysis. Alternatively, the increase in virulence
might have reflected viral evolution within the IDU epidemic. It
has been observed that explosive epidemics (characteristic of early
spread in IDU populations) are associated with slow HIV
evolution [28]. The IDU epidemic in our cohort followed the
same pattern: more than half of all IDU infections were diagnosed
in just six years between 1985–1990. Our findings are also
consistent with a scenario that selection pressure to attain optimal
virulence was weak in the early years of the rapidly expanding
IDU epidemic, but intensified with the slowing of the expansion,
driving virulence towards the levels already attained in the slower
HET and MSM epidemics. Differences in the time trends of the
viral setpoint were less pronounced between the exposure
categories, and we have shown that the increasing trend of the
setpoint had only a minor role in the time trend towards steeper
CD4 decline.
Finally, we note that the overall median of the rate of CD4
decline was faster in the Swiss HIV Cohort Study (55 cells/mL/
year) that had stable virulence than in the Italian MASTER cohort
(50 cells/mL/year) that showed increasing virulence. This
observation and the finding of converging levels of virulence
among the riskgroups of the MASTER cohort are consistent with,
but do not provide direct evidence for, the hypothesis that HIV
has evolved close to the level of virulence that is optimal for its
transmission [29], and local epidemics started by a founder virus of
less-than-optimal virulence might experience an increase in
virulence (whether by local evolution or repeated introductions).
In contrast, epidemics founded by more virulent viruses might
exhibit stable or even declining virulence.
We conclude that trends and patterns of HIV virulence may
differ between geographical regions and even between different
riskgroups within the same region. The results of individual studies
can therefore not be extrapolated to predict the global patterns of
the evolution of HIV virulence.
Methods
Study population and the calculation of virulence
markers
The Italian MASTER (Management Standardizzato di Terapia
Antiretrovirale) Cohort is a prospective longitudinal multicenter
cohort comprising the general HIV patient population in referral
centres throughout Italy. The analyses were restricted to patients
of Italian nationality and white ethnicity for best representation of
the local epidemics, and to the three major exposure categories:
heterosexually infected patients (HET), intravenous drug users
(IDU) and men having sex with men (MSM). Patients under age
15 were excluded from the analysis.
Markers of virulence were defined as in [17]. Briefly, we
calculated two markers of virulence in antiretroviral naı ¨ve patients:
the linear slope of the decline of the CD4 count and the mean log
virus load (setpoint) of each patient. Serial measurements of CD4
cell counts and plasma RNA determinations for all registered
HIV Trends in Italy
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points preceding the first initiation of antiretroviral treatment in
each patient were included in the analysis. The infections were
dated to the earliest date of confirmed HIV-1 infection in the
patients. To eliminate confounding effects of primary and late-
stage infection, we discarded data points obtained within 200 days
after the earliest date of confirmed infection in each patient, and
data points obtained after the first CD4 count below 100 cells/mL.
The viral setpoint was calculated in patients who had at least three
remaining RNA measurements spanning at least 100 days, as the
mean log10 virus load per mL. The CD4 slope was estimated by
linear regression in patients who had at least five remaining
measurements of the CD4 count, spanning at least one year. We
have verified that fitting linear decline slopes yielded smaller
residual sums of squared errors than fitting exponential decline.
Analyses of the CD4 slope and the setpoint were restricted to
patients who had their original first CD4 count or RNA
measurement obtained within one year of the earliest date of
confirmed infection.
Statistical analysis
We estimated the effect of the date of confirmed infection on the
virulence markers by analysis of covariance (general linear
models). Categorical factors included gender and exposure
category (riskgroup); reference levels were chosen to reflect the
majority in the study groups. Continuous predictors included the
earliest date of confirmed infection (converted to Julian date), age
at the date of confirmed infection and the baseline CD4+ cell
count, defined as the first CD4+ count obtained at least 200 days
after the earliest date of confirmed infection. The starting models
included the interaction between gender and riskgroup, and two-
way interactions between all pairs of a continuous and a
categorical predictor. Significant effects were assessed by stepwise
elimination of non-significant interaction terms and non-signifi-
cant factors, and finally by merging non-significant levels of
categorical predictors [30].
The time trend of the CD4 slopes was also investigated with
mixed-effect models fitted to the CD4+ T cell counts (relative to
baseline) from all eligible patients over time; the models accounted
for the correlation of repeated measurements within each
individual by random intercept and time slope. The primary
explanatory variable was time since the earliest date of confirmed
infection (estimating the CD4 slope), and the models also included
the interactions of the time with gender, riskgroup, the earliest
date of confirmed infection, age at the date of confirmed infection,
the baseline CD4+ cell count and (in some analyses) the viral
setpoint, to account for the effect of these factors on the CD4
slope; and the 3-way interaction between time, date and riskgroup.
Stepwise elimination of non-significant factors was performed
based on likelihood ratio tests.
All statistical analyses were performed with the R software
package (www.r-project.org).
Moving averages
The datasets of both virulence markers were sorted into
ascending order according to the date of confirmed infection of
each patient. CD4 slope values below the 5% and above the 95%
quantiles were excluded from the analysis. The average of 50
patients was calculated at a time, with the window of averaging
moving along the lists of patients. The first point in each graph
represents the average of the first 50 patients in the respective list;
the second point represents the average of the patients second
through 51
st in the list, etc. Each average was dated on the
horizontal time axis to the mean date of confirmed infection
among the respective 50 patients.
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